NICE, the health technology appraisal institute for England and Wales, has issued final draft guidance recommending Novartis' VEGF-A inhibitor Lucentis (ranibizumab) as a treatment for visual impairment due to choroidal neovascularization secondary to pathological myopia.
NICE, the health technology appraisal institute for England and Wales, has issued final draft guidance recommending Novartis' VEGF-A inhibitor Lucentis (ranibizumab) as a treatment for visual impairment due to choroidal neovascularization secondary to pathological myopia.
NICE recommends it should only be prescribed if it is made available to the NHS as part of a patient access scheme. Novartis has already agreed a patient access scheme...
The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.
The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.
The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.
